| Completed | 2 | 112 | US | Itacitinib, INCB039110, Immune effector cell therapy, CAR-T cell therapy, Placebo, Yescarta, axicabtagene ciloleucel KTE-C19 | Incyte Corporation | Cytokine Release Syndrome | 02/23 | 08/23 | | |
NCT05660421: Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors |
|
|
| Recruiting | 2 | 25 | US | Itacitinib, Corticosteroid, Endoscopic Procedure, Skin biopsy, Biospecimen Collection | Douglas Johnson, Incyte Corporation | Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | 04/26 | 04/27 | | |
